# US 2017/0281810 A1 · Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281810 A1
- Document ID: US20170281810A1
- Status: Published application
- Kind: A1
- Application number: 15/628,143
- Filed: 2017-06-20
- Published: 2017-10-05
- Earliest claimed: 2015-03-19
- Assignees: Zhejiang Dtrm Biopharma Co. Ltd.
- Applicants: Zhejiang Dtrm Biopharma Co. Ltd.
- Inventors: Wei He
- Web page: https://patentgrep.com/patent/US20170281810A1

## CPC

- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4743: condensed with ring systems having sulfur as a ring hetero atom
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/52: Purines, e.g. adenine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 487/04: Ortho-condensed systems
- A61K 31/4162: condensed with heterocyclic ring systems
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.

## Claims

### Claim 1

A method for treating a lymphoid malignancy, comprising administering to a subject in need thereof a therapeutically effective amount of (a) a Bruton tyrosine kinase (BTK) inhibitor, (b) a mammalian target of rapamycin (mTOR) kinase inhibitor, and (c) a B-cell lymphoma 2 (Bcl-2) inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the BTK inhibitor is a compound represented by Formula I, II, Ia, Ib, IIa, or IIb,
wherein:
each R1 is F;
R2 is F;
R3 is H or D;
n is 1, 2, 3 or 4; and
m is 1 or 2,
or an enantiomer, a diastereomer, a pharmaceutically acceptable salt, or a prodrug thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the BTK inhibitor is selected from the group consisting of Compound 1, Compound 2, Compound 3, Compound 4, Compound 5, Compound 6, Compound 7, and Compound 20 as shown in Table 1, or an enantiomer, a diastereomer, a pharmaceutically acceptable salt, or a prodrug thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the BTK inhibitor is ibrutinib or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the mTOR kinase inhibitor is everolimus or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mTOR kinase inhibitor is rapamycin or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the Bcl-2 inhibitor is venetoclax or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the lymphoid malignancy is selected from the group consisting of diffuse large B-cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia (WM), and mantle cell lymphoma (MCL).

### Claim 9

A method for treating an immune disorder, comprising administering to a subject in need thereof a therapeutically effective amount of (a) a Bruton tyrosine kinase (BTK) inhibitor, and (b) a mammalian target of rapamycin (mTOR) kinase inhibitor.

### Claim 10 (depends on 9)

The method of claim 9, wherein the BTK inhibitor is a compound represented by Formula I, II, Ia, Ib, IIa, or IIb,
wherein:
each R1 is F;
R2 is F;
R3 is H or D;
n is 1, 2, 3 or 4; and
m is 1 or 2,
or an enantiomer, a diastereomer, a pharmaceutically acceptable salt, or a prodrug thereof.

### Claim 11 (depends on 9)

The method of claim 9, wherein the BTK inhibitor is selected from the group consisting of Compound 1, Compound 2, Compound 3, Compound 4, Compound 5, Compound 6, Compound 7, and Compound 20 as shown in Table 1, or an enantiomer, a diastereomer, a pharmaceutically acceptable salt, or a prodrug thereof.

### Claim 12 (depends on 9)

The method of claim 9, wherein the BTK inhibitor is ibrutinib or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 9)

The method of claim 9, wherein the mTOR kinase inhibitor is everolimus or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 9)

The method of claim 9, wherein the mTOR kinase inhibitor is rapamycin or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 9)

The method of claim 9, wherein the immune disorder is an autoimmune disease.

### Claim 16 (depends on 15)

The method of claim 15, wherein the autoimmune disease is rheumatoid arthritis or systemic lupus erythematosus.

### Claim 17

A pharmaceutical composition comprising a Bruton tyrosine kinase (BTK) inhibitor, a mammalian target of rapamycin (mTOR) kinase inhibitor, and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the composition comprises
(i) ibrutinib, Compound 3, or Compound 5; and
(ii) everolimus or rapamycin.

### Claim 19 (depends on 17)

The pharmaceutical composition of claim 17, further comprising an immunomodulatory drug (IMiD).

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the composition comprises
(i) ibrutinib, Compound 3, or Compound 5;
(ii) everolimus or rapamycin; and
(iii) thalidomide, revlimid, or pomalidomide.

### Claim 21 (depends on 17)

The pharmaceutical composition of claim 17, further comprising a Bcl-2 inhibitor.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the composition comprises
(i) ibrutinib, Compound 3, or Compound 5;
(ii) everolimus or rapamycin; and
(iii) venetoclax or navitoclasx.

### Claim 23

A method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of (a) a Bruton tyrosine kinase (BTK) inhibitor, and (b) a mammalian target of rapamycin (mTOR) kinase inhibitor.

### Claim 24 (depends on 23)

The method of claim 23, wherein the BTK inhibitor is a compound represented by Formula I, II, Ia, Ib, IIa, or IIb,
wherein:
each R1 is F;
R2 is F;
R3 is H or D;
n is 1, 2, 3 or 4; and
m is 1 or 2,
or an enantiomer, a diastereomer, a pharmaceutically acceptable salt, or a prodrug thereof.

### Claim 25 (depends on 23)

The method of claim 23, wherein the BTK inhibitor is selected from the group consisting of Compound 1, Compound 2, Compound 3, Compound 4, Compound 5, Compound 6, Compound 7, and Compound 20 as shown in Table 1, or an enantiomer, a diastereomer, a pharmaceutically acceptable salt, or a prodrug thereof.

### Claim 26 (depends on 23)

The method of claim 23, wherein the BTK inhibitor is ibrutinib or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 23)

The method of claim 23, wherein the mTOR kinase inhibitor is everolimus or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 23)

The method of claim 23, wherein the mTOR kinase inhibitor is rapamycin or a pharmaceutically acceptable salt thereof.

### Claim 29 (depends on 23)

The method of claim 23, wherein the cancer is a solid tumor.

### Claim 30 (depends on 29)

The method of claim 29, wherein the solid tumor is lymphoma.
